Researchers have identified a new type of blood-based biomarker test for Alzheimer’s disease that measures structural changes in proteins, providing more information on the underlying biology of the disease than standard blood tests. The findings, published in Nature Aging, also provide new insights into how Alzheimer’s disease biology may differ between males and females.
“This work introduces a fundamentally new, blood-based approach to detecting and staging Alzheimer’s disease,” said Dr. Richard Hodes, director of NIH’s National Institute on Aging (NIA). “By revealing protein structural changes associated with genetic risk, symptom severity, and sex differences—features not captured by existing biomarkers—this research could enable earlier diagnosis and more effective clinical trials.”






